Financial support and resources available for businesses impacted by COVID-19.

Support for businesses impacted by COVID-19.

logo of Conjuchem
Exited company

Conjuchem

Details
Region
Quebec
Industry sector
Medical/health
Investment year
1998
Fund
Healthcare Venture Fund
Learn More
About the company

ConjuChem creates novel, next-generation medicines using unique, long-acting therapeutic peptides. Underlying all ConjuChem compounds are bioconjugation platforms called Drug Affinity Complex (DACTM) and Preformed Conjugate-Drug Affinity Complex (PC-DACTM). When applied to a given peptide, DACTM and PC-DACTM can create new drugs with similar therapeutic activities but with significantly longer durations of activity and improved safety profiles.